- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850028
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma
Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide Zirconium-89 (89Zr) and studied in solid malignancies (NCT02453984). The results of atezolizumab biodistribution can help to get a better understanding of the response mechanisms, the relation with minimal residual disease, the relation with the status of the T-cell and natural killer (NK)-cell repertoire and toxicity of programmed death ligand 1 (PDL1) checkpoint inhibition. Possibly in the future this will facilitate optimal patient selection. Sequential 89Zr-atezolizumab positron emission tomography (PET) scans can provide information on the dynamics of atezolizumab biodistribution over time. In combination with repeated characterization of tumor tissue and blood samples, these results can give inside in primary and acquired resistance.
In this parallel study of the HOVON 151 trial, 89Zr-atezolizumab-PET-scans will be used to evaluate 20 high risk DLBCL patients before and after induction (R-CHOP) therapy, and at suspected relapse during or after atezolizumab consolidation (HOVON 151).
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with a high risk diffuse large B-cell lymphoma (DLBLC) with an international prognostic score (IPI) > 2, have a high risk of relapse even after achieving a metabolic complete remission with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) chemo-immunotherapy. Outcome after relapse is dismal. In patients with varies types of relapsed lymphoma checkpoint inhibition have shown promising results.
In order to improve outcome patients with a high risk DLBCL will be treated in the HOVON 151 trial (EudracT 2017-002605-35) with the monoclonal antibody directed against the immune checkpoint program death ligand 1 (PDL1) atezolizumab for 1 year after achieving a complete metabolic remission with R-CHOP.
The observed percentage of PDL1 positive tumor cells in DLBCL cases ranges from 13 to 31%. For PD-1/PDL1 checkpoint inhibition PDL1 tumor surface expression was proposed as a potential predictive marker. Despite higher overall response rates in PDL1 positive malignancies compared to PDL1 negative tumors, responses are seen in PDL1 negative patients nevertheless. PDL1 status from resected specimens showed a poor correlation to the PDL1 status from matched biopsies. Furthermore it has been shown that PDL1 expression in tumor biopsies changes with treatment. Therefore, PDL1 expression assessed by one single biopsy might not be representative.
Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide Zirconium-89 (89Zr) and studied in solid malignancies (NCT02453984). The results of atezolizumab biodistribution can help to get a better understanding of the response mechanisms, the relation with minimal residual disease, the relation with the status of the T-cell and natural killer (NK)-cell repertoire and toxicity of programmed death ligand 1 (PDL1) checkpoint inhibition. Possibly in the future this will facilitate optimal patient selections. Sequential 89Zr-atezolizumab PET scans can provide information on the dynamics of atezolizumab biodistribution over time. In combination with repeated characterization of tumor tissue and blood samples, these results can give inside in the primary and acquired resistance.
In this parallel study of the HOVON 151 trial, 89Zr-atezolizumab-PET-scans will be used to evaluate 20 high risk DLBCL patients before and after induction (R-CHOP) therapy, and at suspected relapse during or after atezolizumab consolidation (HOVON 151).
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xaver U. Kahle, MD
- Phone Number: +31503612530
- Email: x.kahle@umcg.nl
Study Contact Backup
- Name: Marcel Nijland, MD
- Phone Number: +31503614582
- Email: m.nijland@umcg.nl
Study Locations
-
-
-
Groningen, Netherlands, 9100 RB
- University Medical Center Groningen
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1081HV
- VU University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 (inclusive) years
- Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) based upon a representative histology specimen according to the World Health Organization (WHO) classification, revision 2016 (see appendix A)
- Ann Arbor stages II-IV (see appendix B)
- WHO performance status 0 - 1 (see appendix E)
- international prognostic index (IPI) ≥ 3 at diagnosis (see appendix C)
- Negative pregnancy test at study entry
- Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
- Written informed consent
- Patient is capable of giving a written informed consent
Exclusion Criteria:
Diagnosis
- All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016 (see appendix A), including:
- High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations
- Testicular large B-cell lymphoma
- Primary mediastinal B cell lymphoma
- Transformed indolent lymphoma
- Post-transplant lymphoproliferative disorder
Organ dysfunction
- Clinical signs of severe pulmonary dysfunction
- Clinical signs of heart failure (NYHA classification II-IV)
- Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
- Myocardial infarction during the last 6 months
- Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min
Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:
CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females) / (0.815 x serum creatinine [μmol/L])
- Inadequate hematological function: hemoglobin < 5.5 mmol/L,absolute neutrophil count (ANC) < 1.0x10^9/L or platelets < 75x10^9 /L
- Spontaneous international normalized ratio (INR) > 1.5, activated partial thromboplastin time (aPTT) >33
- Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.
- Clinical signs of severe cerebral dysfunction
- Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- Major surgery within the last 4 weeks
Known or suspected infection
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before date of registration. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay
- Patients known to be human immunodeficiency virus (HIV)-positive
- Active chronic hepatitis B or C infection
- Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab
Auto-immune
- Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest CT scan at screening.
- Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
- Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than non-Hodgkin lymphoma (NHL) at a dose equivalent to < 30 mg/day prednisone/prednisolone.
General
- Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)
- Current participation in another clinical trial interfering with this trial
- History of active cancer during the past 5 years, except basal cell carcinoma of the skin or stage 0 cervical carcinoma
- Life expectancy < 6 months
- Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Prior treatment
- Prior treatment with atezolizumab, or anti PD1 or PDL1 antibodies.
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapeutic antibodies.
- Treatment with systemic immunostimulatory agents (including but not limited to interferon (IFN), interleukin (IL)-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to date of registration.
- Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti- tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Imaging cohort
All study participants will be allocated to this arm (single-arm study).
Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
|
The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning. These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biodistribution of 89Zr-atezolizumab
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
The biodistribution of the tracer 89Zr-atezolizumab as assessed with 89Zr-atezolizumab PET scans.
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PDL1 and human leukocyte antigen (HLA) expression using immunohistochemistry (IHC)
Time Frame: IHC for PDL1 and HLA expression on archival tumor tissue will be performed after initial biopsy at time of diagnosis.
|
Tumor and immune cell PDL1 and HLA expression on archival pre-treatment biopsy via IHC.
|
IHC for PDL1 and HLA expression on archival tumor tissue will be performed after initial biopsy at time of diagnosis.
|
Soluble programmed death ligand 1 (sPDL1) measurement using an enzyme-linked immunosorbent assay (ELISA).
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
sPDL1 serum levels will be determined with ELISA
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Gene expression profiling (GEP) via Nanostring
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
GEP via Nanostring analysis for cell-of origin will be perfomed on archival, paraffin fixed biopsies.
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Next generation sequencing (NGS) data
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Mutational analysis will be perfomed on archival, paraffin fixed biopsies.
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T- and NK-cell dynamics in response to R-CHOP therapy
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Multi-parameter flowcytometry will be used to assess baseline and post induction-therapy status of the T- and NK-cell repertoire.
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Gut microbiome dynamics in response to R-CHOP therapy
Time Frame: From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Baseline and post induction-therapy fecal samples will be collected for NGS analysis
|
From 2 weeks before R-CHOP until 52 weeks after R-CHOP
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marcel Nijland, MD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201700599
- 2017-003511-20 (EudraCT Number)
- NL63047.042.18 (Other Identifier: CCMO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
-
National Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
-
University of WashingtonGenentech, Inc.RecruitingPrimary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNektar TherapeuticsRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditionsUnited States
-
Chongqing University Cancer HospitalRecruitingDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedChina
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingDiffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeUnited States
-
David Bond, MDRecruitingRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditionsUnited States
Clinical Trials on 89Zr-atezolizumab PET scans
-
University Medical Center GroningenTerminatedLobular Metastatic Breast CancerNetherlands
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Memorial Sloan Kettering Cancer CenterCompletedMultiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
Karolinska University HospitalRecruitingMetastatic Triple-Negative Breast CarcinomaSweden
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)CompletedWounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in IndiansHeart Diseases | Cardiovascular Diseases
-
University Medical Center GroningenRecruiting
-
London Health Sciences CentreCompleted
-
Institut Cancerologie de l'OuestATONCOCompleted